Blog

  • Hidden mirror world or just imagination? Scientist says dark matter comes from this unknown plane!

    Hidden mirror world or just imagination? Scientist says dark matter comes from this unknown plane!

    The nature and origins of dark matter remain among the greatest mysteries in modern physics. While some theories point towards its existence, making up around 80% of the universe’s matter, scientists still have no clear answer about what dark matter actually is.Recently, a physicist proposed two new ideas that could give a new perspective to the presently known information about dark matter.

    Does dark matter come from a ‘hidden mirror world‘?

    Profumo, a physicist based in the US, published a new study on July 8, 2025, in Physical Review D, where he shared an interesting idea that explores the possibility that dark matter comes from a hidden “shadow world” that mirrors our own. In this shadow world, there could be dark versions of particles like quarks and gluons that stick together to form heavy particles, kind of like the ones that make up atoms in our universe.In the early days of the universe, these dark particles could have clumped together under gravity to form stable, super-small black holes, or similar objects that wouldn’t interact with regular matter or light, but only gravity, which makes them invisible but still capable of shaping the universe. Profumo says this could explain all the dark matter that scientists believe is out there but haven’t been able to detect.

    Representative Image

    This idea builds on the “mirror matter” theory that’s been around for years. It suggests there might be a parallel universe running alongside ours, made up of similar particles and physics, but completely hidden, except for the tiny gravitational effects we can observe (MDPI).

    He also gave dark matter theories earlier

    A study published in May in Physical Review D by Profumo suggested a completely different idea about where dark matter might come from. He said that it could have been created as radiation from the edge of the universe, specifically during a phase of rapid expansion right after the Big Bang, known as the quasi–de Sitter phase.

    Representative Image

    This theory applies quantum physics to the fabric of the expanding universe. It proposes that stable dark matter particles could have been “frozen in” from the heat at the universe’s outer horizon, like cosmic leftovers locked in place during expansion. Depending on how the early universe evolved, these particles could have a wide range of masses, from tiny to extremely heavy, close to the Planck scale.Interestingly, it doesn’t require dark matter to interact with anything from the Standard Model of physics

    Why are these theories important

    According to Phys.org, Profumo says, “Both mechanisms are highly speculative, but they offer self‑contained and calculable scenarios that don’t rely on conventional particle dark matter models, which are increasingly under pressure from null experimental results”. These ideas don’t depend on the weakly interacting massive particle (WIMP) paradigm, which has not been detected so far, but are based on well-known physics principles that have been extended to new horizons.Future studies could refine these theories, as even if one or both ideas prove incorrect, they tell how innovative thinking and established physics can combine to challenge our assumptions and bring us closer to solving the dark matter puzzle.


    Continue Reading

  • Liver Health: Can supplements cause liver failure? Top US doctor reveals THESE safety tips |

    Liver Health: Can supplements cause liver failure? Top US doctor reveals THESE safety tips |

    The booming supplement market often preys on young people’s insecurities, with wellness gurus promoting potentially harmful products. Unlike supplements prescribed by medical professionals tailored to individual needs, these unregulated multivitamins and gummies promising beauty enhancements may not be effective or safe. Concerns arise about the potential for organ failure due to these supplements.

    The supplement market is booming, and most of them are feeding on the insecurities of young people. While the supplements advised by qualified medical professionals are curated to your individual needs, the ones promoted by wellness gurus can often be harmful. You might have come across many multivitamins and gummies claiming to improve skin, strengthen nails, or hair. But do they really work? Most importantly, are these supplements even safe?

    Can supplements cause organ failure

    supplement

    A young woman recently revealed that she took multivitamins for hair, nails, and skin health, and instead of the promised benefits, she ended up in a hospital with organ failure. Her skin, urine, and eyes became yellow, and the doctors found that her liver was dangerously damaged. So, can you end up in an emergency room for ‘just’ taking the vitamins? Dr. Joseph Salhab, a leading gastroenterologist based in Florida, with expertise in liver health, has recently explained what must have gone wrong. “I’m seeing more cases of liver failure due to certain harmful supplements. We’re seeing an eightfold increase in liver failure. And in fact, 15 million Americans may be taking supplements that are harmful to their liver,” Dr. Salhab said in a video shared on Instagram.

    How do supplements backfire

    supplement

    Supplements are supposed to substitute to the shortcomings in the body and improve health. But how do they backfire?“It’s not because supplements are inherently bad. In fact, there are a lot of good, beneficial supplements. But the problem is, is that the safety data for a supplement does not have to be proven before it hits the shelf, and anyone can make them. That means your favorite supplement can be contaminated with harmful ingredients and additives,” he said.

    Supplements that damage the liver

    Common liver diseases to know

    The gastroenterologist also stated that certain supplements can cause liver damage and even liver failure. Why? “Because anyone can make them, they can be contaminated, and they don’t have to prove safety before you buy them,” he said. The doctor also listed some common supplements that can cause liver failure. These include:

    • Turmeric/Curcumin supplements
    • Green tea extract
    • Weight loss supplements
    • Kava
    • Black cohosh
    • Unregulated herbal remedies imported from other countries with unknown ingredients

    How to stay safe

    supplement

    (Pic courtesy: iStock)

    Dr. Salhab also shared some tips to stay safe while taking supplements.

    • Ensure the product is made by a reputable manufacturer/ company
    • Ensure the ingredients are third-party verified
    • A website named Liver Talks can tell you whether a supplement or ingredient has had documented cases of liver problems
    • Regular liver checkups (every few months)

    Top Supplements for Men’s Health Over 30

    “The test I use is called a CMP. And always make sure that you tell your doctor about any supplements you’re taking to make sure it’s not interacting with anything,” he said. Disclaimer:This article is for informational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional before starting or stopping any supplement.


    Continue Reading

  • A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies | Molecular Neurodegeneration

    A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies | Molecular Neurodegeneration

  • Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–90. https://doi.org/10.1016/s0006-291x(84)80190-4.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Alzheimer A. Uber eigenartige Erkrankung der Hirnrinde. All Z Psychiatr. 1907;64:146–8.

    Google Scholar 

  • Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci. 1986;83:4913–7. https://doi.org/10.1073/pnas.83.13.4913.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20:5143–69. https://doi.org/10.1002/alz.13859.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–8. https://doi.org/10.1016/0165-6147(91)90609-v.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–98. https://doi.org/10.1016/0896-6273(91)90052-2.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306–18. https://doi.org/10.1038/s41573-022-00391-w.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Dyck CHV, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl Journal of Medicine. 2023;388:9–21. https://doi.org/10.1056/NEJMoa2212948.

    Article 

    Google Scholar 

  • Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–27. https://doi.org/10.1001/jama.2023.13239.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia aging study. Hypertension. 2012;59:780–6. https://doi.org/10.1161/hypertensionaha.111.178962.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54:412–36. https://doi.org/10.1038/s41588-022-01024-z.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Morris MC, Evans DA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol. 2003;60:194–200. https://doi.org/10.1001/archneur.60.2.194.

    Article 
    PubMed 

    Google Scholar 

  • Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.

    Article 
    PubMed 

    Google Scholar 

  • U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation. Early Alzheimer’s disease: developing drugs for treatment, guidelines for industry. 2018.

  • Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168–70. https://doi.org/10.1126/science.6474172.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59. https://doi.org/10.1007/bf00308809.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800. https://doi.org/10.1212/wnl.58.12.1791.

    Article 
    PubMed 

    Google Scholar 

  • Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nat Med. 2021;27:871–81. https://doi.org/10.1038/s41591-021-01309-6.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9:197–210. https://doi.org/10.14283/jpad.2022.30.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856–61. https://doi.org/10.1038/nm1438.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Brinkmalm G, Hong W, Wang Z, et al. Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer’s brain. Brain. 2019;142:1441–57. https://doi.org/10.1093/brain/awz066.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Petit D, Fernández SG, Zoltowska KM, et al. Aβ profiles generated by Alzheimer’s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry. 2022;27:2821–32. https://doi.org/10.1038/s41380-022-01518-6.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schultz SA, Liu L, Schultz AP, et al. γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 2024;23:913–24. https://doi.org/10.1016/s1474-4422(24)00236-9.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Walsh DM, Minogue AM, Sala Frigerio C, et al. The APP family of proteins: similarities and differences. Biochem Soc Trans. 2007;35:416–20. https://doi.org/10.1042/bst0350416.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hellstrand E, Boland B, Walsh DM, Linse S. Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem Neurosci. 2010;1:13–8. https://doi.org/10.1021/cn900015v.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Linse S. Toward the equilibrium and kinetics of amyloid peptide self-assembly. Curr Opin Struct Biol. 2021;70:87–98. https://doi.org/10.1016/j.sbi.2021.05.004.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Yan Jin IG, Yun-Ju Cheng, Ilke Tunali, Sergey Shcherbinin, David Perahia, Krista Phipps, Kevin Biglan, Mark Mintun, Matan Dabora, Miroslaw Brys, editor Safety and Amyloid Plaque Reduction Effects of Remternetug in Patients with Alzheimer’s Disease: Interim Analysis from a Phase 1 Study. Gothernburg: 2023 AD/PD Conference; 2023.

  • Demattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012;76:908–20. https://doi.org/10.1016/j.neuron.2012.10.029.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003.

    Article 
    PubMed 

    Google Scholar 

  • Hampel H, Elhage A, Cho M, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414–24. https://doi.org/10.1093/brain/awad188.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362–77. https://doi.org/10.14283/jpad.2023.30.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Luka Kulic FA, Gregory Klein, Carsten Hofmann, Stella Yilmaz, João A. Abrantes, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, editor Latest interim results from the Brainshuttle AD study, a phase 1b/2a study of trontinemab in people with Alzheimer’s disease. J Prev Alzheimer’s Dis. 2025;12(Suppl 1):Abstract LB02.

  • Bateman RJ, Smith J, Donohue MC, et al. Two phase 3 trials of gantenerumab in early Alzheimer’s disease. N Engl J Med. 2023;389:1862–76. https://doi.org/10.1056/NEJMoa2304430.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49–60. https://doi.org/10.1016/j.neuron.2013.10.061.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Weber F, Bohrmann B, Niewoehner J, et al. Brain shuttle antibody for Alzheimer’s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Rep. 2018;22:149–62. https://doi.org/10.1016/j.celrep.2017.12.019.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pizzo ME, Plowey ED, Khoury N, et al. Engineering anti-amyloid antibodies with transferrin receptor targeting improves safety and brain biodistribution. bioRxiv 2024:2024.2007.2026.604664. https://doi.org/10.1101/2024.07.26.604664.

  • Wang YJ, Gao CY, Yang M, et al. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer’s disease. Brain Behav Immun. 2010;24:1281–93. https://doi.org/10.1016/j.bbi.2010.05.010.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shimada M, Abe S, Takahashi T, et al. Prophylaxis and treatment of Alzheimer’s disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PLoS One. 2013;8: e57606. https://doi.org/10.1371/journal.pone.0057606.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Senior K. Dosing in phase II trial of Alzheimer’s vaccine suspended. Lancet Neurol. 2002;1:3. https://doi.org/10.1016/s1474-4422(02)00023-6.

    Article 
    PubMed 

    Google Scholar 

  • Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824–8. https://doi.org/10.1038/nrn938.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–62. https://doi.org/10.1212/01.Wnl.0000159740.16984.3c.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003;38:547–54. https://doi.org/10.1016/s0896-6273(03)00294-0.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448–52. https://doi.org/10.1038/nm840.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Nicoll JAR, Buckland GR, Harrison CH, et al. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease. Brain. 2019;142:2113–26. https://doi.org/10.1093/brain/awz142.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • McDade E, Voytyuk I, Aisen P, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol. 2021;17:703–14. https://doi.org/10.1038/s41582-021-00545-1.

    Article 
    PubMed 

    Google Scholar 

  • Sperling R, Henley D, Aisen PS, et al. Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b/3 clinical trial. JAMA Neurol. 2021;78:293–301. https://doi.org/10.1001/jamaneurol.2020.4857.

    Article 
    PubMed 

    Google Scholar 

  • Nordvall G, Lundkvist J, Sandin J. Gamma-secretase modulators: a promising route for the treatment of Alzheimer’s disease. Front Mol Neurosci. 2023;16: 1279740. https://doi.org/10.3389/fnmol.2023.1279740.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vaz M, Silvestre S. Alzheimer’s disease: recent treatment strategies. Eur J Pharmacol. 2020;887: 173554. https://doi.org/10.1016/j.ejphar.2020.173554.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 2020;77:199–209. https://doi.org/10.1001/jamaneurol.2019.3988.

    Article 
    PubMed 

    Google Scholar 

  • Henley D, Raghavan N, Sperling R, et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N Engl J Med. 2019;380:1483–5. https://doi.org/10.1056/NEJMc1813435.

    Article 
    PubMed 

    Google Scholar 

  • Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med. 2019;380:1408–20. https://doi.org/10.1056/NEJMoa1812840.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cebers G, Alexander RC, Haeberlein SB, et al. AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease. Journal of Alzheimer’s Disease. 2017;55:1039–53. https://doi.org/10.3233/jad-160701.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Sci Transl Med. 2016;8:363ra150. https://doi.org/10.1126/scitranslmed.aad9704.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2018;378:1691–703. https://doi.org/10.1056/NEJMoa1706441.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50. https://doi.org/10.1056/NEJMoa1210951.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Coric V, Salloway S, van Dyck CH, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72:1324–33. https://doi.org/10.1001/jamaneurol.2015.0607.

    Article 
    PubMed 

    Google Scholar 

  • Hou P, Zielonka M, Serneels L, et al. The γ-secretase substrate proteome and its role in cell signaling regulation. Mol Cell. 2023;83:4106-4122.e4110. https://doi.org/10.1016/j.molcel.2023.10.029.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518–22. https://doi.org/10.1038/19083.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zhou R, Yang G, Guo X, et al. Recognition of the amyloid precursor protein by human γ-secretase. Science. 2019;363:363. https://doi.org/10.1126/science.aaw0930.

    Article 
    CAS 

    Google Scholar 

  • De Strooper B, Karran E. New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases. EMBO J. 2024;43:887–903. https://doi.org/10.1038/s44318-024-00057-w.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kasri A, Camporesi E, Gkanatsiou E, et al. Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome. Acta Neuropathol. 2024;148:8. https://doi.org/10.1007/s00401-024-02756-4.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lott APD, Alam M, Cantrill C, Croney R, Alcaraz F, Rodríguez Sarmiento RM, Lindemann L, Mueller L, Mueggler T, Vardar T, Tortelli R, Sturm S, Gerlach I, editor RG6289, a new γ-secretase modulator for the treatment of Alzheimer’s disease: Dose selection for a Phase II trial based on population PK/PD modeling. J Prev Alzheimer’s Dis. 2023;10(Suppl 1):Abstract PO17.

  • Cohen S, Ducharme S, Brosch JR, et al. Single ascending dose results from an ongoing phase 1 study of mivelsiran (ALN-APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease. Alzheimer’s and Dementia. 2024;20:(TBD).

    Google Scholar 

  • Abushakra S, Porsteinsson AP, Sabbagh M, et al. APOLLOE4 phase 3 study of oral ALZ-801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer’s disease: trial design and baseline characteristics. Alzheimers Dement (N Y). 2024;10:e12498. https://doi.org/10.1002/trc2.12498.

    Article 
    PubMed 

    Google Scholar 

  • Zhao Z, Liu Y, Ruan S, Hu Y. Current anti-amyloid-β therapy for Alzheimer’s disease treatment: from clinical research to nanomedicine. Int J Nanomedicine. 2023;18:7825–45. https://doi.org/10.2147/ijn.S444115.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J Biol Chem. 2011;286:38825–32. https://doi.org/10.1074/jbc.R111.288308.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bayer TA. Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease. Mol Psychiatry. 2022;27:1880–5. https://doi.org/10.1038/s41380-021-01409-2.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hartlage-Rübsamen M, Bluhm A, Piechotta A, et al. Immunohistochemical evidence from APP-transgenic mice for glutaminyl cyclase as drug target to diminish pE-abeta formation. Molecules 2018;23. https://doi.org/10.3390/molecules23040924.

  • Hoffmann T, Meyer A, Heiser U, et al. Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer’s disease—studies on relation to effective target occupancy. J Pharmacol Exp Ther. 2017;362:119–30. https://doi.org/10.1124/jpet.117.240614.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Vijverberg EGB, Axelsen TM, Bihlet AR, et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. Alzheimers Res Ther. 2021;13:142. https://doi.org/10.1186/s13195-021-00882-9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vivoryon Therapeutics N.V. Provides update on VIVIAD phase 2b study of varoglutamstat in early Alzheimer’s disease [press release]. 2024. https://www.vivoryon.com/vivoryon-therapeutics-n-v-provides-update-on-viviad-phase-2b-study-of-varoglutamstat-in-earlyalzheimers-disease/.

  • Hu Y, Cho M, Sachdev P, et al. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease. Med. 2024;5:1206–26. https://doi.org/10.1016/j.medj.2024.08.004.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Mueggler T, Portron A, Poirier A, et al. Pharmacodynamic effect of a new γ-secretase modulator, RG6289, on CSF amyloid-β peptides in a randomized phase I study. Alzheimers Dement. 2024;20:e095213. https://doi.org/10.1002/alz.095213.

    Article 

    Google Scholar 

  • Noguchi-Shinohara M, Shuta K, Murakami H, et al. Lecanemab-associated amyloid-β protofibril in cerebrospinal fluid correlates with biomarkers of neurodegeneration in Alzheimer’s disease. Ann Neurol. 2025;97:993–1006. https://doi.org/10.1002/ana.27175.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yang T, Dang Y, Ostaszewski B, et al. Target engagement in an Alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid. Ann Neurol. 2019;86:215–24. https://doi.org/10.1002/ana.25513.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • FDA clears first blood test used in diagnosing alzheimer’s disease [press release]. 2025. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease.

  • Feaster HT, Sundell K, Hyland M, et al. ALTITUDE-AD: use of a validated plasma pTau217 assay to screen potential participants in an ongoing randomized, double-blind, placebo-controlled phase 2 study of sabirnetug for early Alzheimer’s disease (S15.008). Neurology. 2025;104:3870. https://doi.org/10.1212/WNL.0000000000211295.

    Article 

    Google Scholar 

  • Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–704. https://doi.org/10.1056/NEJMoa2100708.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Arboleda-Velasquez JF, Lopera F, O’Hare M, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–3. https://doi.org/10.1038/s41591-019-0611-3.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lopera F, Marino C, Chandrahas AS, et al. Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nat Med. 2023;29:1243–52. https://doi.org/10.1038/s41591-023-02318-3.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019;99:912–28. https://doi.org/10.1038/s41374-019-0197-x.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133:665–704. https://doi.org/10.1007/s00401-017-1707-9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kanmert D, Cantlon A, Muratore CR, et al. C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death. J Neurosci. 2015;35:10851–65. https://doi.org/10.1523/jneurosci.0387-15.2015.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sato C, Barthélemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97:1284-1298.e1287. https://doi.org/10.1016/j.neuron.2018.02.015.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ondrejcak T, Klyubin I, Hu NW, et al. Tau and amyloid β protein in patient-derived aqueous brain extracts act concomitantly to disrupt long-term potentiation in vivo. J Neurosci. 2023;43:5870–9. https://doi.org/10.1523/jneurosci.0082-23.2023.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hu NW, Ondrejcak T, Klyubin I, et al. Patient-derived tau and amyloid-β facilitate long-term depression in vivo: role of tumour necrosis factor-α and the integrated stress response. Brain Commun. 2024;6:fcae333. https://doi.org/10.1093/braincomms/fcae333.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • DeVos SL, Goncharoff DK, Chen G, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33:12887–97. https://doi.org/10.1523/jneurosci.2107-13.2013.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shao E, Chang CW, Li Z, et al. TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model. Sci Transl Med. 2022;14: eabm5527. https://doi.org/10.1126/scitranslmed.abm5527.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chang CW, Shao E, Mucke L. Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science. 2021;371:371. https://doi.org/10.1126/science.abb8255.

    Article 
    CAS 

    Google Scholar 

  • Tai C, Chang CW, Yu GQ, et al. Tau reduction prevents key features of autism in mouse models. Neuron. 2020;106:421-437.e411. https://doi.org/10.1016/j.neuron.2020.01.038.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16:109–20. https://doi.org/10.1038/nrn3887.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci. 2016;17:251–60. https://doi.org/10.1038/nrn.2016.13.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shulman M, Kong J, O’Gorman J, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease. Nat Aging. 2023;3:1591–601. https://doi.org/10.1038/s43587-023-00523-w.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Monteiro C, Toth B, Brunstein F, et al. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: lauriet. Neurology. 2023;101:e1391–401. https://doi.org/10.1212/wnl.0000000000207663.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fleisher AS, Munsie LM, Perahia DGS, et al. Assessment of efficacy and safety of zagotenemab: results from PERISCOPE-ALZ, a phase 2 study in early symptomatic Alzheimer disease. Neurology. 2024;102: e208061. https://doi.org/10.1212/wnl.0000000000208061.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Teng E, Manser PT, Pickthorn K, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79:758–67. https://doi.org/10.1001/jamaneurol.2022.1375.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhou X, Zou H, Lutz MW, et al. Assessing tilavonemab efficacy in early Alzheimer’s disease via longitudinal item response theory modeling. Alzheimers Dement (N Y). 2024;10:e12471. https://doi.org/10.1002/trc2.12471.

    Article 
    PubMed 

    Google Scholar 

  • Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer’s disease. Alzheimers Dement. 2019;15:487–96. https://doi.org/10.1016/j.jalz.2018.09.010.

    Article 
    PubMed 

    Google Scholar 

  • Horie K, Barthélemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain. 2021;144:515–27. https://doi.org/10.1093/brain/awaa373.

    Article 
    PubMed 

    Google Scholar 

  • Horie K, Salvadó G, Barthélemy NR, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat Med. 2023;29:1954–63. https://doi.org/10.1038/s41591-023-02443-z.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Barton ME. editor Results from TOGETHER, a Phase II study of bepranemab in prodromal–mild AD. J Prev Alzheimer’s Dis. 2025;12(Suppl 1):Abstract LBS3.

  • Zhou J, Rawal S, Yagi T, et al. E2814: an anti-tau therapy engages its CNS target and affects the downstream tangle-specific biomarker MTBR-tau243 in dominantly inherited Alzheimer’s disease. Alzheimers Dement. 2023;19:e082771. https://doi.org/10.1002/alz.082771.

    Article 

    Google Scholar 

  • Wildsmith K. editor Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD. J Prev Alzheimer’s Dis. 2025;12(Suppl 1):Abstract OC04.

  • Biundo F, Del Prete D, Zhang H, Arancio O, D’Adamio L. A role for tau in learning, memory and synaptic plasticity. Sci Rep. 2018;8:3184. https://doi.org/10.1038/s41598-018-21596-3.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yi S, Liu Q, Wang X, et al. Tau modulates Schwann cell proliferation, migration and differentiation following peripheral nerve injury. J Cell Sci. 2019;132:132. https://doi.org/10.1242/jcs.222059.

    Article 
    CAS 

    Google Scholar 

  • Ikegami S, Harada A, Hirokawa N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett. 2000;279:129–32. https://doi.org/10.1016/s0304-3940(99)00964-7.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wegmann S, DeVos SL, Zeitler B, et al. Persistent repression of tau in the brain using engineered zinc finger protein transcription factors. Science Advances. 2021;7:eabe1611. https://doi.org/10.1126/sciadv.abe1611.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Edwards AL, Collins JA, Junge C, et al. Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2023;80:1344–52. https://doi.org/10.1001/jamaneurol.2023.3861.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mummery CJ, Börjesson-Hanson A, Blackburn DJ, et al. Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29:1437–47. https://doi.org/10.1038/s41591-023-02326-3.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ziogas N, Wu S, Li Y, et al. Exploratory clinical outcomes from the BIIB080 Phase 1b multiple ascending dose and long term extension study in mild Alzheimer’s disease. J Prev Alzheimer’s Dis. 2023;10(Suppl 1):Abstract LB09.

  • Barker SJ, Thayer MB, Kim C, et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Sci Transl Med. 2024;16: eadi2245. https://doi.org/10.1126/scitranslmed.adi2245.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sela T, Mansø M, Siegel M, et al. Diligent design enables antibody-ASO conjugates with optimal pharmacokinetic properties. Bioconjug Chem. 2023;34:2096–111. https://doi.org/10.1021/acs.bioconjchem.3c00393.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Khare P, Edgecomb SX, Hamadani CM, Tanner EE, Manickam DS. Lipid nanoparticle-mediated drug delivery to the brain. Adv Drug Deliv Rev. 2023;197:114861. https://doi.org/10.1016/j.addr.2023.114861.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673–94. https://doi.org/10.1038/s41573-020-0075-7.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sasso JM, Tenchov R, Wang D, et al. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry. 2023;62:601–23. https://doi.org/10.1021/acs.biochem.2c00245.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lemaitre T, Cornu M, Schwalen F, et al. Molecular glue degraders: exciting opportunities for novel drug discovery. Expert Opin Drug Discov. 2024;19:433–49. https://doi.org/10.1080/17460441.2024.2306845.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Mullard A. Protein degraders push into novel target space. Nat Rev Drug Discov. 2024;23:799–802. https://doi.org/10.1038/d41573-024-00170-9.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sincere NI, Anand K, Ashique S, Yang J, You C. PROTACs: Emerging targeted protein degradation approaches for advanced druggable strategies. Molecules 2023;28. https://doi.org/10.3390/molecules28104014.

  • Pliatsika D, Blatter C, Riedl R. Targeted protein degradation: current molecular targets, localization, and strategies. Drug Discovery Today. 2024;29: 104178. https://doi.org/10.1016/j.drudis.2024.104178.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Yuzwa SA, Cheung AH, Okon M, McIntosh LP, Vocadlo DJ. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J Mol Biol. 2014;426:1736–52. https://doi.org/10.1016/j.jmb.2014.01.004.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zhu Y, Shan X, Yuzwa SA, Vocadlo DJ. The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem. 2014;289:34472–81. https://doi.org/10.1074/jbc.R114.601351.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hastings NB, Wang X, Song L, et al. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener. 2017;12:39. https://doi.org/10.1186/s13024-017-0181-0.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rostgaard N, Jul PH, Garmer M, Volbracht C. Increasing O-GlcNAcylation attenuates tau hyperphosphorylation and behavioral impairment in rTg4510 tauopathy mice. JIN 2023;22. https://doi.org/10.31083/j.jin2205135.

  • Yuzwa SA, Shan X, Jones BA, et al. Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. Mol Neurodegener. 2014;9: 42. https://doi.org/10.1186/1750-1326-9-42.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Graham DL, Gray AJ, Joyce JA, et al. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology. 2014;79:307–13. https://doi.org/10.1016/j.neuropharm.2013.11.025.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Fleisher A, editor. PROSPECT-ALZ: results of the phase 2 study of ceperognastat, an orally available o-linked n-acetyl glucosaminidase inhibitor for the treatment of early symptomatic Alzheimer’s disease. CTAD; 2024.

  • Gonzalez-Rellan MJ, Fondevila MF, Dieguez C, Nogueiras R. O-GlcNAcylation: a sweet hub in the regulation of glucose metabolism in health and disease. Front Endocrinol (Lausanne). 2022;13:873513. https://doi.org/10.3389/fendo.2022.873513.

    Article 
    PubMed 

    Google Scholar 

  • Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017;18:452–65. https://doi.org/10.1038/nrm.2017.22.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Salvadó G, Horie K, Barthélemy NR, et al. Disease staging of Alzheimer’s disease using a CSF-based biomarker model. Nat Aging. 2024;4:694–708. https://doi.org/10.1038/s43587-024-00599-y.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Leuzy A, Raket LL, Villemagne VL, et al. Harmonizing tau positron emission tomography in Alzheimer’s disease: the CenTauR scale and the joint propagation model. Alzheimers Dement. 2024;20:5833–48. https://doi.org/10.1002/alz.13908.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for nuclear medicine and molecular imaging workgroup. Alzheimers Dement. 2025;21: e14338. https://doi.org/10.1002/alz.14338.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Horie K, Li Y, Barthélemy NR, et al. Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in dominantly inherited Alzheimer’s disease. Ann Neurol. 2023;93:1158–72. https://doi.org/10.1002/ana.26620.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Horie K, Salvadó G, Koppisetti RK, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. Nat Med. 2025. https://doi.org/10.1038/s41591-025-03617-7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Florian H, Wang D, Arnold SE, et al. Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study. Brain. 2023;146:2275–84. https://doi.org/10.1093/brain/awad024.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:11282–6. https://doi.org/10.1073/pnas.90.23.11282.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shim KH, Kang MJ, Youn YC, An SSA, Kim S. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease. Alzheimer’s Research & Therapy. 2022;14:201. https://doi.org/10.1186/s13195-022-01150-0.

    Article 
    CAS 

    Google Scholar 

  • Spina S, La Joie R, Petersen C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 2021;144:2186–98. https://doi.org/10.1093/brain/awab099.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cairns NJ, Perrin RJ, Franklin EE, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology. 2015;35:390–400. https://doi.org/10.1111/neup.12205.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32. https://doi.org/10.1186/s13024-019-0333-5.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease. Ann Neurol. 1999;45:353–7. https://doi.org/10.1002/1531-8249(199903)45:3%3c353::aid-ana11%3e3.0.co;2-4.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Marui W, Iseki E, Uéda K, Kosaka K. Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease. J Neurol Sci. 2000;174:81–4. https://doi.org/10.1016/s0022-510x(99)00327-5.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29:1964–70. https://doi.org/10.1038/s41591-023-02449-7.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fraser K, JC, Brown R, Edwards A, Ferber K, Rubel C, Shulman M, Graham D, editors. Distribution of alpha-synuclein co-pathology in mild cognitive impairment (MCI), mild Alzheimer’s disease, and progressive supranuclear palsy clinical trial cohorts. Lisbon: AD/PD; 2024.

  • Majbour NK, Chiasserini D, Vaikath NN, et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease. Sci Rep. 2017;7: 40263. https://doi.org/10.1038/srep40263.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Twohig D, Rodriguez-Vieitez E, Sando SB, et al. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease. Acta Neuropathol Commun. 2018;6:130. https://doi.org/10.1186/s40478-018-0624-z.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bellomo G, Toja A, Paolini Paoletti F, et al. Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement. 2024;20:2444–52. https://doi.org/10.1002/alz.13658.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhang J, Li X, Li JD. The roles of post-translational modifications on α-synuclein in the pathogenesis of Parkinson’s diseases. Front Neurosci. 2019;13: 381. https://doi.org/10.3389/fnins.2019.00381.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11:213–28. https://doi.org/10.2174/0929866043407174.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med. 2022;387:421–32. https://doi.org/10.1056/NEJMoa2202867.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pagano G, Monnet A, Reyes A, et al. Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024. https://doi.org/10.1038/s41591-024-03270-6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Pagano G, Taylor KI, Anzures Cabrera J, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease. Nat Med. 2024;30:1096–103. https://doi.org/10.1038/s41591-024-02886-y.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Singer SZW, Kjærsgaard L, Wiedemann J, Kallunki P, Kompus K, Jørgensen M, Flensburg M, Bidani A, Molinuevo JL, Takeda A, Grønning B, Luthman J. editor Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial [abstract]. Mov Disord. 2024;39(Suppl 1):Abstract 20.

  • Lang AE, Siderowf AD, Macklin EA, et al. Trial of cinpanemab in early Parkinson’s disease. N Engl J Med. 2022;387:408–20. https://doi.org/10.1056/NEJMoa2203395.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75:1206–14. https://doi.org/10.1001/jamaneurol.2018.1487.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fjord-Larsen L, Thougaard A, Wegener KM, et al. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs. 2021;13: 1994690. https://doi.org/10.1080/19420862.2021.1994690.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Weihofen A, Liu Y, Arndt JW, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis. 2019;124:276–88. https://doi.org/10.1016/j.nbd.2018.10.016.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kallunki P, Willén K, Sotty F, et al. The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation. In: Movement disorders. Hoboken: Wiley; 2022.

  • Burré J, Edwards RH, Halliday G, et al. Research priorities on the role of α-synuclein in Parkinson’s disease pathogenesis. Mov Disord. 2024;39:1663–78. https://doi.org/10.1002/mds.29897.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Greten-Harrison B, Polydoro M, Morimoto-Tomita M, et al. αβγ-synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A. 2010;107:19573–8. https://doi.org/10.1073/pnas.1005005107.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cole TA, Zhao H, Collier TJ, et al. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight 2021;6. https://doi.org/10.1172/jci.insight.135633.

  • DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9: eaag0481. https://doi.org/10.1126/scitranslmed.aag0481.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Alnylam. Alnylam R&D day. 2023. https://capella.alnylam.com/wp-content/uploads/2023/12/Alnylam-RD-Day-2023-1.pdf. Accessed 19 Nov 2024.

  • Boike L, Cioffi AG, Majewski FC, et al. Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. Cell Chem Biol. 2021;28:4-13.e17. https://doi.org/10.1016/j.chembiol.2020.09.001.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017;134:819–38. https://doi.org/10.1007/s00401-017-1755-1.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Grossauer A, Hemicker G, Krismer F, et al. α-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis. Mov Disord Clin Pract. 2023;10:737–47. https://doi.org/10.1002/mdc3.13710.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Meilleur K, Seppi K, Krismer F, et al. SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update [abstract]. Mov Disord. 2024;39(Suppl 1):Abstract 644.

  • Burke JR, Roses AD. Genetics of Alzheimer’s disease. Int J Neurol. 1991;25–26:41–51.

    PubMed 

    Google Scholar 

  • Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977–81. https://doi.org/10.1073/pnas.90.5.1977.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–3. https://doi.org/10.1126/science.8346443.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523–7. https://doi.org/10.1038/nature24016.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141-1154.e1147. https://doi.org/10.1016/j.neuron.2018.05.008.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shi Y, Manis M, Long J, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216:2546–61. https://doi.org/10.1084/jem.20190980.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Tcw J, Qian L, Pipalia NH, et al. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell. 2022;185:2213-2233.e2225. https://doi.org/10.1016/j.cell.2022.05.017.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Blanchard JW, Akay LA, Davila-Velderrain J, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611:769–79. https://doi.org/10.1038/s41586-022-05439-w.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Nelson MR, Liu P, Agrawal A, et al. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023;26:2104–21. https://doi.org/10.1038/s41593-023-01480-8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen Y, Song S, Parhizkar S, et al. APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell. 2024;187:428-445.e420. https://doi.org/10.1016/j.cell.2023.11.029.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chemparathy A, Le Guen Y, Chen S, et al. APOE loss-of-function variants: compatible with longevity and associated with resistance to Alzheimer’s disease pathology. Neuron. 2024;112:1110-1116.e1115. https://doi.org/10.1016/j.neuron.2024.01.008.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Haney MS, Pálovics R, Munson CN, et al. APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia. Nature. 2024;628:154–61. https://doi.org/10.1038/s41586-024-07185-7.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci. 2021;15:630502. https://doi.org/10.3389/fnins.2021.630502.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Raulin A-C, Doss SV, Trottier ZA, et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17:72. https://doi.org/10.1186/s13024-022-00574-4.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667. https://doi.org/10.1038/s41467-019-14279-8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fortea J, Pegueroles J, Alcolea D, et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease. Nat Med. 2024;30:1284–91. https://doi.org/10.1038/s41591-024-02931-w.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Vance JM, Farrer LA, Huang Y, et al. Report of the APOE4 National Institute on Aging/Alzheimer disease sequencing project consortium working group: reducing APOE4 in carriers is a therapeutic goal for Alzheimer’s disease. Ann Neurol. 2024;95:625–34. https://doi.org/10.1002/ana.26864.

    Article 
    PubMed 

    Google Scholar 

  • Sepulveda-Falla D, Sanchez JS, Almeida MC, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia. Acta Neuropathol. 2022;144:589–601. https://doi.org/10.1007/s00401-022-02467-8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Quiroz YT, Aguillon D, Aguirre-Acevedo DC, et al. APOE3 christchurch heterozygosity and autosomal dominant Alzheimer’s disease. N Engl J Med. 2024;390:2156–64. https://doi.org/10.1056/NEJMoa2308583.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Snow AD, Cummings JA, Lake T. The unifying hypothesis of Alzheimer’s disease: heparan sulfate proteoglycans/glycosaminoglycans are key as first hypothesized over 30 years ago. Front Aging Neurosci. 2021;13: 710683. https://doi.org/10.3389/fnagi.2021.710683.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fu Y, Zhao J, Atagi Y, et al. Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener. 2016;11:37. https://doi.org/10.1186/s13024-016-0099-y.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Holmes BB, DeVos SL, Kfoury N, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110:E3138-3147. https://doi.org/10.1073/pnas.1301440110.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rauch JN, Luna G, Guzman E, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381–5. https://doi.org/10.1038/s41586-020-2156-5.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yamauchi Y, Deguchi N, Takagi C, et al. Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Biochemistry. 2008;47:6702–10. https://doi.org/10.1021/bi8003999.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease. Mol Neurodegener. 2020;15:63. https://doi.org/10.1186/s13024-020-00413-4.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci Transl Med. 2021;13:13. https://doi.org/10.1126/scitranslmed.aaz4564.

    Article 
    CAS 

    Google Scholar 

  • Yin Z, Rosenzweig N, Kleemann KL, et al. APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints. Nat Immunol. 2023;24:1839–53. https://doi.org/10.1038/s41590-023-01627-6.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu CC, Wang N, Chen Y, et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer’s disease. Nat Immunol. 2023;24:1854–66. https://doi.org/10.1038/s41590-023-01640-9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kim Johnson MK, Stephen Kaminsky, Gianni Amato, Nithya Selvan, Richie Khanna, Sandi See Tai, Ronald Crystal, editor LB4 – Safety and Preliminary Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer’s Disease – Interim Data from a Phase 1/2, Open-Label, 52-Week, Multicenter Study. J Prev Alzheimer’s Dis. 2025;12(Suppl 1):Abstract LB04.

  • Belloy ME, Andrews SJ, Le Guen Y, et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 2023;80:1284–94. https://doi.org/10.1001/jamaneurol.2023.3599.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ferguson CM, Hildebrand S, Godinho B, et al. Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer’s disease. Alzheimers Dement. 2024;20:2632–52. https://doi.org/10.1002/alz.13703.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Litvinchuk A, Huynh TV, Shi Y, et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model. Ann Neurol. 2021;89:952–66. https://doi.org/10.1002/ana.26043.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ferguson CM, Godinho B, Echeverria D, et al. A combinatorial approach for achieving CNS-selective RNAi. Nucleic Acids Res. 2024;52:5273–84. https://doi.org/10.1093/nar/gkae100.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Huynh TV, Liao F, Francis CM, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis. Neuron. 2017;96:1013-1023.e1014. https://doi.org/10.1016/j.neuron.2017.11.014.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. APOE and dementia – resequencing and genotyping in 105,597 individuals. Alzheimers Dement. 2020;16:1624–37. https://doi.org/10.1002/alz.12165.

    Article 
    PubMed 

    Google Scholar 

  • Deza-Lougovski YI, Weiss LM, Horton HM, et al. Circulating apoE4 protein levels from dried blood spots predict cognitive function in a large population-based survey setting. Alzheimers Dement. 2024;20:7613–23. https://doi.org/10.1002/alz.14224.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mak AC, Pullinger CR, Tang LF, et al. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71:1228–36. https://doi.org/10.1001/jamaneurol.2014.2011.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaji S, Berghoff SA, Spieth L, et al. Apolipoprotein E aggregation in microglia initiates Alzheimer’s disease pathology by seeding β-amyloidosis. Immunity. 2024;57:2651-2668.e2612. https://doi.org/10.1016/j.immuni.2024.09.014.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Gratuze M, Jiang H, Wang C, et al. APOE antibody inhibits Aβ-associated tau seeding and spreading in a mouse model. Ann Neurol. 2022;91:847–52. https://doi.org/10.1002/ana.26351.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Xiong M, Jiang H, Serrano JR, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13:13. https://doi.org/10.1126/scitranslmed.abd7522.

    Article 
    CAS 

    Google Scholar 

  • Liao F, Zhang TJ, Jiang H, et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol Commun. 2015;3:70. https://doi.org/10.1186/s40478-015-0250-y.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Blumenfeld J, Yip O, Kim MJ, Huang Y. Cell type-specific roles of APOE4 in Alzheimer disease. Nat Rev Neurosci. 2024;25:91–110. https://doi.org/10.1038/s41583-023-00776-9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Huang Y, Liu XQ, Wyss-Coray T, et al. Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98:8838–43. https://doi.org/10.1073/pnas.151254698.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Harris FM, Brecht WJ, Xu Q, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer’s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A. 2003;100:10966–71. https://doi.org/10.1073/pnas.1434398100.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhao J, Davis MD, Martens YA, et al. APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet. 2017;26:2690–700. https://doi.org/10.1093/hmg/ddx155.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hanson AJ, Bayer-Carter JL, Green PS, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 2013;70:972–80. https://doi.org/10.1001/jamaneurol.2013.396.

    Article 
    PubMed 

    Google Scholar 

  • Liang Y, Lin S, Beyer TP, et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem. 2004;88:623–34. https://doi.org/10.1111/j.1471-4159.2004.02183.x.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets. 2011;15:1085–97. https://doi.org/10.1517/14728222.2011.594043.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Litvinchuk A, Suh JH, Guo JL, et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron. 2024;112:384-403.e388. https://doi.org/10.1016/j.neuron.2023.10.023.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jakobsson T, Treuter E, Gustafsson J, Steffensen KR. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci. 2012;33:394–404. https://doi.org/10.1016/j.tips.2012.03.013.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13:433–44. https://doi.org/10.1038/nrd4280.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zhang Z, Fan Q, Luo X, et al. Brain-restricted mTOR inhibition with binary pharmacology. Nature. 2022;609:822–8. https://doi.org/10.1038/s41586-022-05213-y.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Seneviratne U, Huang Z, Am Ende CW, et al. Photoaffinity labeling and quantitative chemical proteomics identify LXRβ as the functional target of enhancers of astrocytic apoE. Cell Chem Biol. 2021;28:148-157.e147. https://doi.org/10.1016/j.chembiol.2020.09.002.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Marino C, Perez-Corredor P, O’Hare M, et al. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Alzheimers Dement. 2024;20:819–36. https://doi.org/10.1002/alz.13436.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Griswold AJ, Celis K, Bussies PL, et al. Increased APOE ε4 expression is associated with the difference in Alzheimer’s disease risk from diverse ancestral backgrounds. Alzheimers Dement. 2021;17:1179–88. https://doi.org/10.1002/alz.12287.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18. https://doi.org/10.1038/nrneurol.2012.263.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501–18. https://doi.org/10.1038/s41582-019-0228-7.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413–46. https://doi.org/10.1016/s0140-6736(20)30367-6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cummings JL, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2025. Alzheimers Dement (N Y). 2025;11:e70098. https://doi.org/10.1002/trc2.70098.

    Article 
    PubMed 

    Google Scholar 

  • McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ. The informed road map to prevention of Alzheimer Disease: A call to arms. Mol Neurodegener. 2021;16:49. https://doi.org/10.1186/s13024-021-00467-y.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126:479–97. https://doi.org/10.1007/s00401-013-1177-7.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Efthymiou AG, Goate AM. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43. https://doi.org/10.1186/s13024-017-0184-x.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27. https://doi.org/10.1056/NEJMoa1211851.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368:107–16. https://doi.org/10.1056/NEJMoa1211103.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Satoh JI, Tabunoki H, Ishida T, et al. Immunohistochemical characterization of microglia in Nasu-Hakola disease brains. Neuropathology. 2011;31:363–75. https://doi.org/10.1111/j.1440-1789.2010.01174.x.

    Article 
    PubMed 

    Google Scholar 

  • Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2017;217:459–72. https://doi.org/10.1083/jcb.201709069.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Paolicelli RC, Sierra A, Stevens B, et al. Microglia states and nomenclature: a field at its crossroads. Neuron. 2022;110:3458–83. https://doi.org/10.1016/j.neuron.2022.10.020.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Savva GM, Wharton SB, Ince PG, et al. Age, Neuropathology, and Dementia. N Engl J Med. 2009;360:2302–9. https://doi.org/10.1056/NEJMoa0806142.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Cummings J, Aisen PS, DuBois B, et al. Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther. 2016;8:39. https://doi.org/10.1186/s13195-016-0207-9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Salloway SP, Sevingy J, Budur K, et al. Advancing combination therapy for Alzheimer’s disease. Alzheimers Dement (N Y). 2020;6:e12073. https://doi.org/10.1002/trc2.12073.

    Article 
    PubMed 

    Google Scholar 

  • Cummings JL, Osse AML, Kinney JW, Cammann D, Chen J. Alzheimer’s disease: combination therapies and clinical trials for combination therapy development. CNS Drugs. 2024;38:613–24. https://doi.org/10.1007/s40263-024-01103-1.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cummings J, Gold M, Mintun M, et al. Key considerations for combination therapy in Alzheimer’s clinical trials: Perspectives from an expert advisory board convened by the Alzheimer’s drug discovery foundation. J Prev Alzheimers Dis. 2025;12: 100001. https://doi.org/10.1016/j.tjpad.2024.100001.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Des Devel Ther. 2016;10:3267–79. https://doi.org/10.2147/dddt.S86463.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Doherty T, editor. Clinical trial design for concurrent anti-amyloid, anti-tau antibody therapy for sporadic AD. Vienna: AD/PD; 2025.

    Google Scholar 

Continue Reading

  • Pakistan’s Embassy in France organize special event to express solidarity with oppressed Kashmiris – RADIO PAKISTAN

    1. Pakistan’s Embassy in France organize special event to express solidarity with oppressed Kashmiris  RADIO PAKISTAN
    2. Pakistan Embassy in Abu Dhabi observes Youm-e-Istehsal  ptv.com.pk
    3. NA unanimously reaffirms all-out support for Kashmiris  Dawn
    4. Day of Exploitation  The Express Tribune
    5. Kashmir is Pakistan’s jugular vein; no compromise on it: CM Sindh  Dunya News

    Continue Reading

  • Trump declines to weigh in on Israel’s Gaza occupation plan, emphasizes US humanitarian efforts

    Trump declines to weigh in on Israel’s Gaza occupation plan, emphasizes US humanitarian efforts

    US President Donald Trump declined to take a position on whether the United States would support a full Israeli reoccupation of the Gaza Strip while emphasizing ongoing American-led humanitarian efforts in the enclave.

    “As far as the rest of it, I really can’t say. That’s going to be pretty much up to Israel,” Trump told reporters Tuesday when asked whether he would support Israel reoccupying all of Gaza.

    Israeli media reported that Prime Minister Benjamin Netanyahu has decided, with US backing, to push ahead with a full-scale reoccupation of Gaza, targeting areas believed to hold Israeli captives.

    The US is “there now trying to get people fed,” Trump said, adding the country gave $60 million to supply food for the people of Gaza.

    “I know Israel is going to help us with that in terms of distribution…We also have the Arab states (which) are going to help us with that, in terms of the money and possibly distribution. So that’s what I’m focused on,” he said.

    Israeli officials said Netanyahu will convene a meeting of political and military leaders Tuesday to discuss “options” for Gaza after the collapse of indirect ceasefire talks with the Palestinian group Hamas.

    The Israeli army, rejecting international calls for a ceasefire, has pursued a brutal offensive on Gaza since Oct. 7, 2023, killing more than 61,000 Palestinians, almost half of them women and children.

    Israel’s military campaign has devastated the enclave and brought it to the verge of famine.

    Last November, the International Criminal Court issued arrest warrants for Netanyahu and his former Defense Minister Yoav Gallant for war crimes and crimes against humanity in Gaza.

    Israel also faces a genocide case at the International Court of Justice for its war on the enclave.


    Continue Reading

  • Talk of Field Marshal becoming president ‘nonsense’: DG ISPR

    Talk of Field Marshal becoming president ‘nonsense’: DG ISPR

    Field Marshal Asim Munir. — Facebook@ISPROfficial
    • DG ISPR rebukes reports of Field Marshal becoming president.
    • We’ll start from east, says ISPR chief on any future India attack.
    • India can be hit everywhere: military spokesperson.

    Inter-Services Public Relations (ISPR) Director General Lt Gen Ahmed Sharif Chaudhry has firmly refuted reports claiming Chief of Army Staff (COAS) Field Marshal Syed Asim Munir has any intention of becoming the country’s president.

    In an interview with the British journal The Economist, the chief military spokesperson termed such reports of the army chief becoming president as “nonsense”.

    This reaffirmation comes after Prime Minister Shehbaz Sharif in July strongly dismissed the rumours suggesting that President Asif Ali Zardari may be asked to step down or COAS has any ambition to assume the presidency.

    Terming such claims as “mere speculation,” the premier assured that there was no truth to the reports circulating in certain sections of the media.

    Speaking to The News on the matter, the prime minister categorically stated: “Field Marshal Asim Munir has never expressed any desire to become the president, nor is there any such plan in the offing.” He emphasised that the trio of President Zardari, Field Marshal Asim Munir, and he himself share a relationship built on mutual respect and a common goal — the progress and prosperity of Pakistan.

    PM Shehbaz’s clarification came after Interior Minister Mohsin Naqvi, in a statement shared on his official X handle, denounced what he called a “malicious campaign” targeting President Zardari, Prime Minister Shehbaz Sharif and the Army Chief.

    “We are fully aware of who is behind the malicious campaign,” said Naqvi, who is considered close to the top military leadership. “I have categorically stated that there has been no discussion, nor does any such idea exist, about the president being asked to resign or the COAS aspiring to assume the presidency,” he added.

    Meanwhile, DG ISPR, while responding to a question about how Pakistan would react if India repeats any act of aggression,  Lt Gen Ahmed Sharif Chaudhry said that Pakistan would begin by striking deeper within India. “We’ll start from the east. “They [India] also need to understand that they can be hit everywhere,” he added.

    Earlier in May, Pakistan and India engaged in the military confrontation triggered by an attack in April on tourists in Indian Illegally Occupied Jammu and Kashmir (IIOJK) that New Delhi blamed on Islamabad, before agreeing to a ceasefire.

    In response to the Indian aggression, Pakistan’s armed forces launched a large-scale retaliatory military action, named “Operation Bunyan-um-Marsoos”, and targeted several Indian military targets across multiple regions.

    Pakistan downed six Indian fighter jets, including three Rafales, and dozens of drones. After at least 87 hours, the war between the two nuclear-armed nations ended on May 10 with a ceasefire agreement brokered by the US.

    The ceasefire was first announced by US President Donald Trump on social media after Washington held talks with both sides, but India has differed with Trump’s claims that it resulted from his intervention and threats to sever trade talks.

    However, Pakistan has acknowledged Trump’s efforts and formally recommended him for the 2026 Nobel Peace Prize, citing his role in defusing tensions between Islamabad and New Delhi last month.


    Continue Reading

  • Everything to know before Season 2 premieres on Netflix

    Everything to know before Season 2 premieres on Netflix

    As Wednesday Season 2 prepares to debut on August 8, audiences are eager to revisit the supernatural world of Nevermore Academy.

    Season 1 follows Wednesday Addams (Jenna Ortega) as she joins Nevermore, a school for outcasts, after being expelled for defending her brother. There, she uncovers dark secrets while investigating a series of murders in the nearby town of Jericho. Her psychic visions and connections to her ancestor Goody Addams reveal a prophecy that hints she may destroy Nevermore.

    Wednesday’s strained relationships soon evolve into alliances. She befriends her werewolf roommate Enid, clashes with siren Bianca, and attracts the attention of Xavier.

    Her bond with normie Tyler grows, but her visions reveal he’s the Hyde, a murderous creature controlled by Laurel Gates—posing as teacher Ms Thornhill. Together, they plan to resurrect Jericho’s founder, Joseph Crackstone, using Wednesday’s blood.

    In the season finale, Goody helps Wednesday survive a fatal wound, and she, alongside Bianca and Enid, defeats Crackstone, Tyler, and Laurel. Principal Weems is killed during the conflict.

    The season ends on a cliffhanger as Xavier gifts Wednesday a phone, and she immediately receives threatening texts from a stalker.

    With classes suspended and unresolved mysteries looming, the stage is set for Season 2. The new season will reportedly explore deeper threats and emotional stakes, including the fate of Enid.

    Wednesday Season 2 will be released in two parts on Netflix, with the first half dropping on August 6 at 12 am PT/ 3 am ET and the second on September 3. 

     

    Continue Reading

  • NA moves to vacate PTI’s Sheikh Waqas Akram’s seat over his absence for 40 days – Pakistan

    NA moves to vacate PTI’s Sheikh Waqas Akram’s seat over his absence for 40 days – Pakistan

    A motion has been made to terminate the membership of Pakistan Tehreek-e-Insaf (PTI) member Sheikh Waqas Akram for his prolonged absence from the National Assembly.

    National Assembly speaker Ayaz Sadiq, told the House that Sheikh Waqas Akram has been absent without any notice for the past 40 days.

    According to the speaker, he cited parliamentary rules that any member can move a motion to vacate the seat, and upon approval of the motion, the seat can be declared vacant.

    In response, PML-N member Nousheen Iftikhar moved an immediate motion, in which it was taken that Sheikh Waqas Akram’s seat should be declared vacant due to his continuous absence.

    The speaker in response explained that according to the rules, he is bound to present this motion for a vote in the House within seven days, while the House has the power to postpone, reject or approve the motion.

    The opposition opposed the motion and raised questions about the attendance of Nawaz Sharif and Hamza Shahbaz.

    However, according to the Assembly Secretariat, the leave requests of both leaders are on record, while no written information or request has been received from Sheikh Waqas Akram.

    According to the rules of the Assembly, even if Sheikh Waqas’s attendance or leave request is received later, the motion presented by Nousheen Iftikhar will remain effective, as the decision on it will have to be taken by the opinion of the House.

    In the related development, the Election Commission of Pakistan (ECP) has disqualified 9senators, including prominent leaders such as opposition leader in the Senate Shibli Faraz and the Opposition leader in the National Assembly Omar Ayub.

    Others disqualified include Sahibzada Hamid Raza, Zartaj Gul, Junaid Afzal Sahi, Muhammad Ansar Iqbal, Rai Hassan Nawaz, Rai Haider Ali, and Rai Murtaza Iqbal.

    It should be noted that the Election Commission of Pakistan has disqualified 9 senators and members of the National Assembly of Pakistan Tehreek-e-Insaf. According to the notification issued, those disqualified include Opposition Leader in the Senate Shibli Faraz, Leader of the Opposition in the National Assembly Omar Ayub, Sahibzada Hamid Raza, Zartaj Gul, Junaid Afzal Sahi, Muhammad Ansar Iqbal, Rai Hassan Nawaz, Rai Haider Ali and Rai Murtaza Iqbal.

    According to the Election Commission, all these members have been disqualified under the Constitution after being convicted by the courts in the cases of May 9.

    Continue Reading

  • Riot Games’ 2XKO translation glitch turns Vi into Bi, Bai, and Blitzorank, sparking confusion amidst gamers | Esports News

    Riot Games’ 2XKO translation glitch turns Vi into Bi, Bai, and Blitzorank, sparking confusion amidst gamers | Esports News

    The upcoming fighting game by Riot Games, 2XKO, hit a bizarre translation malfunction, which was caught by one of the gamers. As reported, it throws a spotlight on the popular champion Vi, altering the name and description of the character. Players across varied regions reported seeing her name change from Vi, to Bi, Bai and even Blitzorank, sparking amusement and confusion within the gaming community.

    Translation glitch turns Riot Games 2XKO’s Vi into multiple names

    The entire issue surfaced as players attempted to translate Piltover enforcer Vi’s official page from Korean to English. Instead of showing her correct name and description, the automated translation system produced some baffling variations. Vi translation glitch turned the character reveal into a confusing spectacle. While some players saw Bisexual (never associated with official Vi character description) under her title, others saw Bye, Bai and Blitzorank.The entire mistranslation did not stop at Vi’s name but even went ahead to her description and region—Zaun became Jaun. It even translated her likes—fisting, instead of showing punching—altered. Vi champion type also got equally mangled. Instead of showing “Offensive” champion type, it showed “No attack whatsoever.”Gamers were quick to take this issue to social media, sharing screenshots and with many joking about this unexpected change, while others listing about the significant breakdown or rather Riot Games localization issue in system. This glitch seems to have stemmed from different interpretations of Vi, leading to some strange results.

    Who is Riot Games 2XKO’s champion, Vi?

    Amidst all the translation chaos, the actual description of Riot Games for Vi in 2XKO paints the character’s clear picture. She is officially the “Executioner of Piltover.” She has been defined as a fierce fighter. Vi’s combat style leverages the Hextech Gauntlet and slick boxing footwork. It allows the champion to excel at closing distances. It also lets her deal some heavy blows.

    Vi, the Piltover Enforcer – Dev Update | 2XKO

    Vi hails from Zaun and has been classified as an Offensive champion type. Her personality has been said to be designed as a rebellious, ultra-aggressive brawler that’s capable of carrying enemies and executing extended combo attacks. This description, which is consistent with League of Legends’ background, stands in stark contrast to all the jumbled-up identities that have been produced by faulty translation.Riot Games has yet to officially address this glitch. However, the community is not waiting. Discussions and memes are continuously spreading around. Whether or not that would be fixed before the 2XKO closed beta release in September 2025 remains to be seen.


    Continue Reading

  • TV tonight: Johnny Vegas’s lovely public art project | Television

    TV tonight: Johnny Vegas’s lovely public art project | Television

    Johnny Vegas: Art, ADHD and Me

    9pm, Channel 4
    Johnny Vegas (and his “longsuffering personal assistant” Bev) is hugely endearing in this two-parter following his public art project. The comedian graduated from art college 25 years ago and is committed to making a sculpture that gives something back to his beloved home town of St Helens – a welcome departure from other recent celebrity art exhibitions. His journey was filmed over four years; along the way, we see him navigate a diagnosis of attention deficit hyperactivity disorder. Hollie Richardson

    MasterChef

    8pm, BBC One
    The BBC has made the surprising decision to air the new series of the long-running cooking competition, despite the judges Gregg Wallace and John Torode having been sacked. Fans and contestants – although not Sarah Shafi, who has been edited out after telling the show’s producers she did not want it to be broadcast – may argue that their enjoyment shouldn’t be ruined because of the action taken. HR

    Destination X

    9pm, BBC One

    Where on Earth? Looking for clues on Destination X. Photograph: BBC/TwoFour

    Rob Brydon’s competition blindfolds contestants, sends them on a bus around Europe and asks them to guess where they are at the end of each episode. With so many red herrings and impossibly hard clues, applying logic feels futile. Still, it’s weirdly addictive. HR

    The Moors Murders: A Search for Justice

    9pm, BBC Two
    Nearly 60 years have passed since Ian Brady and Myra Hindley were tried and convicted, but the remains of a 12-year-old victim, Keith Bennett, are yet to be found. The second episode of this documentary continues to analyse new evidence and leads in the hope of finally bringing the case to a close. Ellen E Jones

    The Fortune Hotel

    9pm, ITV1
    If Jet2 holidays did The Traitors … Stephen Mangan returns as a trickster Caribbean hotel manager who gives each team of two guests a suitcase – most of them empty, one with an “early checkout card” in it and another holding a £250,000 prize. Before they start guessing and swapping, they need to get into the hotel – but there isn’t room for everyone. HR

    Air India Crash: What Went Wrong?

    10pm, Channel 4
    A quick turnaround enables this documentary to assess, two months on, why a London-bound Air India jet hit buildings in Ahmedabad just after takeoff, killing 260 people. Experts sift through theories involving pilot error and failures of software and electrical systems. Jack Seale

    Live sport

    The Hundred cricket: Manchester Originals v Southern Brave 3pm, Sky Sports Main Event. The women’s game is followed by the men’s at 6pm.

    Continue Reading